Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JADE Compare: Abrocitinib vs Dupilumab in Atopic Dermatitis
NCT03720470Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of abrocitinib in atopic dermatitis (AD), sponsored by Pfizer. Started Oct 2018; status: completed.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03720470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720470.